No­vo Nordisk sees more to GLP-1's fu­ture in $600M pact with Flag­ship's Metaphore

No­vo Nordisk is pair­ing up with an­oth­er Flag­ship-found­ed biotech to cre­ate new obe­si­ty med­ica­tions, and GLP-1 re­mains in the frame.

The Dan­ish phar­ma gi­ant, which …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER